Condition
Diabetes Mellitus, Type 2
Locations
Australia, Canada, India, Korea, Republic of, United States
Start date
18/03/2024
Identifiers
Trial ID
NN9541-4945,
NCT number NCT06326047,
Eudract number Not Available
NCT number NCT06326047,
Eudract number Not Available
Summary
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Trial Overview:
Treatment
DRUG: NNC0519-0130
DRUG: Placebo
DRUG: Trizepatide
Study type
INTERVENTIONAL
Trial duration
Mar 18 2024 - Oct 13 2025
Participants
288
Phase
II
Are you eligible?
Gender
Male and female
Age
18 to 75 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.